Secondary efficacy end points
Outcome measure . | Rivipansel (N = 173) . | Placebo (N = 172) . | P value . | Hazard ratio . |
---|---|---|---|---|
Time to discharge, median (95% CI), h | 86.8 (71.3-98.7) | 90.7 (72.1-108.6) | .72 | 0.96 |
Cumulative IV opioid use, median, morphine-equivalent units/kg | 2.30 | 2.36 | .85∗ | [Ratio of medians = 1.01] |
Time to discontinuation of IV opioids, median (95% CI), h | 67.2 (53.3-80.5) | 68.5 (53.8-85.0) | .86 | 1.02 |
Outcome measure . | Rivipansel (N = 173) . | Placebo (N = 172) . | P value . | Hazard ratio . |
---|---|---|---|---|
Time to discharge, median (95% CI), h | 86.8 (71.3-98.7) | 90.7 (72.1-108.6) | .72 | 0.96 |
Cumulative IV opioid use, median, morphine-equivalent units/kg | 2.30 | 2.36 | .85∗ | [Ratio of medians = 1.01] |
Time to discontinuation of IV opioids, median (95% CI), h | 67.2 (53.3-80.5) | 68.5 (53.8-85.0) | .86 | 1.02 |
Based on a rank analysis of covariance model.